- [Resource Hub](/)
- [Resource](/?resource-type=poster#library)
- Detection and retrieval of multiple myeloma cells with single cell molecular confirmation from peripheral blood by multi-parameter immunofluorescence, automated scanning and image analysis

# Detection and retrieval of multiple myeloma cells with single cell molecular confirmation from peripheral blood by multi-parameter immunofluorescence, automated scanning and image analysis

Multiple myeloma is assessed by bone marrow aspirate, an invasive procedure that limits how often the disease can be monitored; this AACR 2018 poster reports a 5-parameter immunofluorescence assay that detected, retrieved and molecularly confirmed myeloma cells in a patient's peripheral blood.

Presented by RareCyte and All4Cure.

Read or download to see:

- A 5-parameter immunofluorescence assay identified myeloma cells in peripheral blood at 55 cells per mL. In a pre-treatment patient sample, cells with a CD138+, CD56+, CD38- and CD45- phenotype were counted at 55 per mL of whole blood; buffy coats were separated from 7.5 mL draws with AccuCyte, stained for CD138, CD38, CD56, CD45 and a nuclear dye, and scanned on CyteFinder.

- Retrieved single cells carried the patient's own tumor mutations, confirming their identity. Cells picked individually with the CytePicker module were whole-genome amplified and Sanger sequenced against four genes taken from the patient's bone marrow genomic profile (IDH1, NRAS, PHLDA1, RPH3AL); mutations were found in 9 of 15 myeloma cells and in 0 of 13 white blood cell controls.

- The same panel also identified normal plasma cells in healthy donors, at 5 per mL. Plasma cells co-expressing CD138 and CD38 were identified at 5 per mL of whole blood in healthy volunteer samples; RPMI8226 myeloma cells spiked into normal donor blood provided the model system used to develop the assay, and patient samples were run under an IRB-approved protocol.

[Download poster](https://cdn.sanity.io/files/s3p6uqps/production/257e56c91de4f4e70aad955abebf6608cf38256c.pdf)

Your browser doesn’t support embedded PDFs.
[Download the poster](https://cdn.sanity.io/files/s3p6uqps/production/257e56c91de4f4e70aad955abebf6608cf38256c.pdf) to view it.

[Back to all resources](/#library)
## Related resources
[Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) CyteFinder SelectScience
### Measuring versus reading – transforming the field of quantitative pathology
[Read Article](https://www.selectscience.net/product-news/measuring-versus-reading-transforming-the-field-of-quantitative-pathology?artid=58733) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) CyteFinder
### CyteFinder II HT
[View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyyz/455452/220141/TS20_103.pdf) [Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) CyteFinder
### CyteFinder II
[View Spec Sheet](https://go.pardot.com/l/455452/2019-11-18/7mzyz2/455452/220143/TS20_104.pdf) [Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) CyteFinder Journal of Clinical Oncology 2026
### Clinical validation of circulating tumor cell synaptophysin and androgen receptor expression in metastatic prostate cancer phenotypes.
[View Publication](https://doi.org/10.1200/JCO.2026.44.16_suppl.5041) [Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) CyteFinder 2026
### Dr. Pashtoon Kasi on the impact of circulating tumor cells on clinical research
[Watch Video](https://www.youtube.com/watch?v=_oGC1KRVN2U) [Publication](https://doi.org/10.1038/s41587-026-03099-z) CyteFinder Nature Biotechnology 2026
### mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression
[View Publication](https://doi.org/10.1038/s41587-026-03099-z) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) CyteFinder Cancer Immunology Research 2026
### Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618831/) [Publication](https://doi.org/10.1097/pai.0000000000001311) CyteFinder Applied Immunohistochemistry & Molecular Morphology 2026
### Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
[View Publication](https://doi.org/10.1097/pai.0000000000001311) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) CyteFinder Nature Communications 2026
### Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12881594/) [Publication](https://doi.org/10.1016/j.ejso.2025.111357) CyteFinder European Journal of Surgical Oncology 2026
### Circulating tumor cells predict relapse in head and neck mucosal squamous cell carcinoma
[View Publication](https://doi.org/10.1016/j.ejso.2025.111357) [Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) CyteFinder Cancer Research Communications 2026
### Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
[View Publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805936/) [Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244) CyteFinder Clinical Cancer Research 2025
### Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma
[View Publication](https://doi.org/10.1158/1078-0432.CCR-25-0244)